@mitsenkov.bsky.social , Senior Bioinformatician at AlphaFold DB, will be giving a keynote talk for EHA’s Computational Biology Training in Hematology programme, speaking with haematologists about structural biology and practical AlphaFold DB use-cases.
#AlphaFold #EHA2026
#AlphaFold #EHA2026
April 15, 2026 at 10:28 AM
@mitsenkov.bsky.social , Senior Bioinformatician at AlphaFold DB, will be giving a keynote talk for EHA’s Computational Biology Training in Hematology programme, speaking with haematologists about structural biology and practical AlphaFold DB use-cases.
#AlphaFold #EHA2026
#AlphaFold #EHA2026
Abstract submission for the Mol Hem Workshop is now open here ehaweb.org/connect-netw...
Submit for your chance to present your latest unpublished work in a highly visible session that forms part of the EHA annual meeting program in Stockholm.
Submit for your chance to present your latest unpublished work in a highly visible session that forms part of the EHA annual meeting program in Stockholm.
EHA2026 Molecular Hematopoiesis Workshop - The European Hematology Association (EHA)
ehaweb.org
March 6, 2026 at 3:26 PM
Abstract submission for the Mol Hem Workshop is now open here ehaweb.org/connect-netw...
Submit for your chance to present your latest unpublished work in a highly visible session that forms part of the EHA annual meeting program in Stockholm.
Submit for your chance to present your latest unpublished work in a highly visible session that forms part of the EHA annual meeting program in Stockholm.
We look forward to attending #EHA2026 and connecting with the global hematology community. Heading to Stockholm? Visit us at booth G1.01 (Hall C) - reach out to our team to learn more: spkl.io/633257B0Ud
June 9, 2026 at 4:00 PM
We look forward to attending #EHA2026 and connecting with the global hematology community. Heading to Stockholm? Visit us at booth G1.01 (Hall C) - reach out to our team to learn more: spkl.io/633257B0Ud
How is frontline immunosuppressive therapy for aplastic anemia evolving in 2026?
Join the next Aplastic Anemia Clinical Case Webinar focusing on highlights from #EHA2026 and practical, evidence-based strategies for patient management.
Register now: https://ow.ly/MGah50ZbipY
Join the next Aplastic Anemia Clinical Case Webinar focusing on highlights from #EHA2026 and practical, evidence-based strategies for patient management.
Register now: https://ow.ly/MGah50ZbipY
June 12, 2026 at 7:35 PM
How is frontline immunosuppressive therapy for aplastic anemia evolving in 2026?
Join the next Aplastic Anemia Clinical Case Webinar focusing on highlights from #EHA2026 and practical, evidence-based strategies for patient management.
Register now: https://ow.ly/MGah50ZbipY
Join the next Aplastic Anemia Clinical Case Webinar focusing on highlights from #EHA2026 and practical, evidence-based strategies for patient management.
Register now: https://ow.ly/MGah50ZbipY
Last chances to submit your abstract for the EHA Molecular Hemopoiesis workshop! ehaweb.org/connect-netw...
Abstract submission closes on April 6th!
Abstract submission closes on April 6th!
EHA2026 Molecular Hematopoiesis Workshop - The European Hematology Association (EHA)
ehaweb.org
April 2, 2026 at 1:36 PM
Last chances to submit your abstract for the EHA Molecular Hemopoiesis workshop! ehaweb.org/connect-netw...
Abstract submission closes on April 6th!
Abstract submission closes on April 6th!
Talquetamab–daratumumab, with or without pomalidomide, led to longer progression-free survival than daratumumab-based standard care in relapsed or refractory myeloma. More than 75% of patients had grade 3 or higher adverse events. Full MonumenTAL-3 trial results: https://nej.md/4ojBcCL
#EHA2026
#EHA2026
June 13, 2026 at 10:05 AM
Talquetamab–daratumumab, with or without pomalidomide, led to longer progression-free survival than daratumumab-based standard care in relapsed or refractory myeloma. More than 75% of patients had grade 3 or higher adverse events. Full MonumenTAL-3 trial results: https://nej.md/4ojBcCL
#EHA2026
#EHA2026
"Essentially, we're moving the factory to the patient's own body..."
Ying Huang, Ph.D., CEO of Legend Biotech on how their novel in vivo CAR T-cell construct aims to remove traditional manufacturing barriers for lymphoma patients. #EHA2026
Ying Huang, Ph.D., CEO of Legend Biotech on how their novel in vivo CAR T-cell construct aims to remove traditional manufacturing barriers for lymphoma patients. #EHA2026
August 26, 2026 at 1:28 AM
"Essentially, we're moving the factory to the patient's own body..."
Ying Huang, Ph.D., CEO of Legend Biotech on how their novel in vivo CAR T-cell construct aims to remove traditional manufacturing barriers for lymphoma patients. #EHA2026
Ying Huang, Ph.D., CEO of Legend Biotech on how their novel in vivo CAR T-cell construct aims to remove traditional manufacturing barriers for lymphoma patients. #EHA2026
@salmantongarcia.bsky.social represented our team at the #EHA2026 Congress in Stockholm, connecting with leading experts and exploring the latest developments in hematology. Great conversations, valuable insights, and new perspectives to bring back to our work.
#Hematology #Healthcare
#Hematology #Healthcare
June 22, 2026 at 9:42 AM
@salmantongarcia.bsky.social represented our team at the #EHA2026 Congress in Stockholm, connecting with leading experts and exploring the latest developments in hematology. Great conversations, valuable insights, and new perspectives to bring back to our work.
#Hematology #Healthcare
#Hematology #Healthcare
At #EHA2026, Dr. Rami Komrokji of @moffittnews.bsky.social discusses the top MDS highlights from the summer meetings.
July 24, 2026 at 10:02 PM
At #EHA2026, Dr. Rami Komrokji of @moffittnews.bsky.social discusses the top MDS highlights from the summer meetings.
Great to speak at #EHA2026 in Stockholm! Many thanks for the kind invitation and to chair Jette Lengefeld for leading the session. It was a pleasure to share the stage with Nicola Vannini and Maria Carolina Florian.
June 16, 2026 at 2:41 PM
Great to speak at #EHA2026 in Stockholm! Many thanks for the kind invitation and to chair Jette Lengefeld for leading the session. It was a pleasure to share the stage with Nicola Vannini and Maria Carolina Florian.
European Hematology Association (EHA) Congress June 11-14, 2026. In person and virtual attendance options. Early registration fee until May 4, 2026. ehaweb.org/connect-netw...
EHA2026 Congress - The European Hematology Association (EHA)
ehaweb.org
March 18, 2026 at 4:57 PM
European Hematology Association (EHA) Congress June 11-14, 2026. In person and virtual attendance options. Early registration fee until May 4, 2026. ehaweb.org/connect-netw...
At #EHA2026, Prof Carsten Niemann discusses prospective validation of CLL-TIM, a machine-learning model predicting severe infection or treatment need within 2 years in newly diagnosed, asymptomatic CLL. Watch the full interview👉https://bit.ly/4x2NT8x #CLL #Haematology
CLL TIM risk model predicts infection and treatment need in newly diagnosed chronic lymphocytic leukaemia - ecancer
Prof Carsten Niemann speaks to ecancer about the first prospective, multicenter validation of the Chronic Lymphocytic Leukemia Treatment-Infection Model (CLL-TI
bit.ly
August 17, 2026 at 4:30 PM
At #EHA2026, Prof Carsten Niemann discusses prospective validation of CLL-TIM, a machine-learning model predicting severe infection or treatment need within 2 years in newly diagnosed, asymptomatic CLL. Watch the full interview👉https://bit.ly/4x2NT8x #CLL #Haematology
Congratulations to Butterfly PhD student Dr. Miguel Vieira Martins @themaximacenter.bsky.social, for presenting his latest research at the recent EHA Congress: medimix.be/hematology/e....
Every presentation, every discussion, and every shared discovery brings us one step closer to better treatments.
Every presentation, every discussion, and every shared discovery brings us one step closer to better treatments.
EHA STOCKHOLM 2026 - Medimix Hematology
From 11 to 14 June 2026: EHA2026 CongressYour direct line with StockholmThe EHA2026 Congress brings together the international hematology community in Stockholm, Sweden.This reimagined edition offers ...
medimix.be
July 13, 2026 at 5:05 PM
Congratulations to Butterfly PhD student Dr. Miguel Vieira Martins @themaximacenter.bsky.social, for presenting his latest research at the recent EHA Congress: medimix.be/hematology/e....
Every presentation, every discussion, and every shared discovery brings us one step closer to better treatments.
Every presentation, every discussion, and every shared discovery brings us one step closer to better treatments.
Frangoul et al. report the results of interim analyses of two phase 3 studies of exa-cel, a gene-edited cellular therapy, in children with transfusion-dependent β-thalassemia or sickle cell disease. Full results of the CLIMB THAL-141 and CLIMB SCD-151 studies: https://nej.md/4osTMsj
#EHA2026
#EHA2026
June 11, 2026 at 6:05 AM
Frangoul et al. report the results of interim analyses of two phase 3 studies of exa-cel, a gene-edited cellular therapy, in children with transfusion-dependent β-thalassemia or sickle cell disease. Full results of the CLIMB THAL-141 and CLIMB SCD-151 studies: https://nej.md/4osTMsj
#EHA2026
#EHA2026
#News for #investors and #media: We're excited to be at #ASCO26 and #EHA2026, where we will share data on how we're delivering a meaningful impact for cancer patients today while innovating for tomorrow.
Learn more: gsk.to/49hUlis
Learn more: gsk.to/49hUlis
May 26, 2026 at 1:07 PM
#News for #investors and #media: We're excited to be at #ASCO26 and #EHA2026, where we will share data on how we're delivering a meaningful impact for cancer patients today while innovating for tomorrow.
Learn more: gsk.to/49hUlis
Learn more: gsk.to/49hUlis
#EHA2026 simultaneous publication by @ghayasissa et al:
The All-Oral Combination of Revumenib, Decitabine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (SAVE)
Read the full article: https://bit.ly/4ofhU1k
The All-Oral Combination of Revumenib, Decitabine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (SAVE)
Read the full article: https://bit.ly/4ofhU1k
June 11, 2026 at 6:10 AM
#EHA2026 simultaneous publication by @ghayasissa et al:
The All-Oral Combination of Revumenib, Decitabine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (SAVE)
Read the full article: https://bit.ly/4ofhU1k
The All-Oral Combination of Revumenib, Decitabine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (SAVE)
Read the full article: https://bit.ly/4ofhU1k
We are excited to announce that Dave Lewis received an award for ENRICH study at the European Haematology Association Congress in Stockholm for 'Best European Research' #EHA2026 @plymuni.bsky.social #clinicaltrials #research #ENRICH
June 16, 2026 at 1:44 PM
We are excited to announce that Dave Lewis received an award for ENRICH study at the European Haematology Association Congress in Stockholm for 'Best European Research' #EHA2026 @plymuni.bsky.social #clinicaltrials #research #ENRICH
At #EHA2026, Matthew Davids, MD, MMSc discusses phase 3 BRUIN CLL 322 results showing fixed-duration pirtobrutinib plus venetoclax and rituximab improved PFS vs SoC in previously treated CLL/SLL. Watch his interview👉https://bit.ly/4xYnE3x #CLL #Haematology #Oncology
Pirtobrutinib plus venetoclax rituximab improves PFS in previously treated CLL and SLL - ecancer
Dr Matthew Davids speaks to ecancer about results from the phase 3 BRUIN CLL 322 trial evaluating fixed-duration pirtobrutinib, a noncovalent BTK inhibitor, in
bit.ly
August 13, 2026 at 11:27 AM
At #EHA2026, Matthew Davids, MD, MMSc discusses phase 3 BRUIN CLL 322 results showing fixed-duration pirtobrutinib plus venetoclax and rituximab improved PFS vs SoC in previously treated CLL/SLL. Watch his interview👉https://bit.ly/4xYnE3x #CLL #Haematology #Oncology
"The idea is, if you reduce the number of pathogenic IgG, you don't tag the red cells for destruction, and you improve anemia control..." Dr. Irina Murakhovskaya of @einsteinmededu.bsky.social discusses the mechanism of nipocalumab. #EHA2026
sohoinsider.com/meetings-con...
sohoinsider.com/meetings-con...
July 10, 2026 at 10:40 PM
"The idea is, if you reduce the number of pathogenic IgG, you don't tag the red cells for destruction, and you improve anemia control..." Dr. Irina Murakhovskaya of @einsteinmededu.bsky.social discusses the mechanism of nipocalumab. #EHA2026
sohoinsider.com/meetings-con...
sohoinsider.com/meetings-con...
"There is a 52% reduction of the probability of progression or death."
Dr. Meletios A. Dimopoulos of National and Kapodistrian University of Athens shares primary data from the phase 3 SUCCESSOR-2 trial at #EHA2026
sohoinsider.com/roundtable-d...
Dr. Meletios A. Dimopoulos of National and Kapodistrian University of Athens shares primary data from the phase 3 SUCCESSOR-2 trial at #EHA2026
sohoinsider.com/roundtable-d...
July 6, 2026 at 3:06 PM
"There is a 52% reduction of the probability of progression or death."
Dr. Meletios A. Dimopoulos of National and Kapodistrian University of Athens shares primary data from the phase 3 SUCCESSOR-2 trial at #EHA2026
sohoinsider.com/roundtable-d...
Dr. Meletios A. Dimopoulos of National and Kapodistrian University of Athens shares primary data from the phase 3 SUCCESSOR-2 trial at #EHA2026
sohoinsider.com/roundtable-d...
Saturday at the European Hematology Association (EHA) Congress, Dr. Amer Zeidan and Dr. Nikolai Podolsev presented study results during the 'Novel Treatments in #AML' session at #EHA26.
pag.virtual-meeting.org/EHA/eha2026/...
@yale-hematology.bsky.social
pag.virtual-meeting.org/EHA/eha2026/...
@yale-hematology.bsky.social
June 15, 2026 at 11:53 AM
Saturday at the European Hematology Association (EHA) Congress, Dr. Amer Zeidan and Dr. Nikolai Podolsev presented study results during the 'Novel Treatments in #AML' session at #EHA26.
pag.virtual-meeting.org/EHA/eha2026/...
@yale-hematology.bsky.social
pag.virtual-meeting.org/EHA/eha2026/...
@yale-hematology.bsky.social
Great to present our latest translational findings from the COALITION study at the 2026 Congress of the European Hematology Association (EHA)(EHA2026) in Stockholm.
This work was conducted at the @petermaccc.bsky.social and explores how CD4⁺ T cells contribute to responses to glofitamab.
This work was conducted at the @petermaccc.bsky.social and explores how CD4⁺ T cells contribute to responses to glofitamab.
July 3, 2026 at 11:40 PM
Great to present our latest translational findings from the COALITION study at the 2026 Congress of the European Hematology Association (EHA)(EHA2026) in Stockholm.
This work was conducted at the @petermaccc.bsky.social and explores how CD4⁺ T cells contribute to responses to glofitamab.
This work was conducted at the @petermaccc.bsky.social and explores how CD4⁺ T cells contribute to responses to glofitamab.